Compare IGR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGR | IRWD |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 741.8M |
| IPO Year | N/A | 2009 |
| Metric | IGR | IRWD |
|---|---|---|
| Price | $4.72 | $3.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | 763.9K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $23.17 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.20 | $0.55 |
| 52 Week High | $5.37 | $5.78 |
| Indicator | IGR | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 42.79 |
| Support Level | $4.65 | $3.08 |
| Resistance Level | $5.04 | $3.93 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 22.22 | 39.72 |
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.